EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GLP-1 receptor agonists in idiopathic subglottic stenosis: patient attitudes, barriers, facilitators and patient-reported outcomes

Laura-Elisabeth Gosselin, Catherine Anderson, Chadwan Al Yaghchi

European Archives of Oto-Rhino-Laryngology · 21.11.2026

DOI: 10.1007/s00405-026-10835-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Archives of Oto-Rhino-Laryngology, online erschienen am 21.11.2026. Verfasst von Laura-Elisabeth Gosselin und 2 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Idiopathic subglottic stenosis (iSGS) is a rare disease of unknown etiology. There has been a growing interest within the patient community regarding the potential therapeutic role of GLP-1 receptor agonists (GLP-1 RA) in the management of iSGS, potentially through weight loss-mediated or direct anti-inflammatory mechanisms. The objective of this study was to evaluate patient perspectives and attitudes regarding the potential role of GLP-1 RA in the overall management of iSGS.

Methods

We conducted a cross-sectional observational study through a structured online anonymous survey. The survey comprised 53 items organized across four domains: demographics; attitudes, barriers and facilitators to GLP-1 RA use; therapy details and adverse effects; and perceived therapeutic impact.

Results

A total of 1382 patients with iSGS completed the survey. Diagnostic delay of iSGS was a prominent finding, with patients reporting a substantial lag between symptom onset and confirmed diagnosis. Overall, 407 patients used GLP-1 RA therapy. Among GLP-1 RA users, 38.44% self-reported perceived improvement in airway symptoms. Key barriers to GLP-1 RA therapy included cost, access, and limited physician awareness. Thematic analysis of the patient’s responses revealed patients’ attitudes toward GLP-1 RA therapy were largely favorable, with patients citing anti-inflammatory benefits and quality of life improvements as primary motivators for use.

Conclusion

GLP-1 receptor agonists are generally viewed favorably by patients with iSGS. Patient-reported experiences suggest possible improvements in airway symptoms, although prospective studies are required to establish causality and clarify mechanistic benefit.

Zitieren

APA

Gosselin, L., Anderson, C., & Yaghchi, C. A. (2026). GLP-1 receptor agonists in idiopathic subglottic stenosis: patient attitudes, barriers, facilitators and patient-reported outcomes. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-026-10835-3

Vancouver

Gosselin L, Anderson C, Yaghchi CA. GLP-1 receptor agonists in idiopathic subglottic stenosis: patient attitudes, barriers, facilitators and patient-reported outcomes. European Archives of Oto-Rhino-Laryngology. 2026. doi:10.1007/s00405-026-10835-3

BibTeX
@article{Gosselin2026,
  author = {Gosselin, Laura-Elisabeth and Anderson, Catherine and Yaghchi, Chadwan Al},
  title = {GLP-1 receptor agonists in idiopathic subglottic stenosis: patient attitudes, barriers, facilitators and patient-reported outcomes},
  journal = {European Archives of Oto-Rhino-Laryngology},
  year = {2026},
  doi = {10.1007/s00405-026-10835-3}
}
Kostenlos starten →